Consano Bio completed an oversubscribed financing exceeding its $15 million target to fund its Phase 1 trial and continued development of C-1101.
- Amount
- $15M
- Announced
- 5 October 2026
- Use of funds
- Complete ongoing Phase 1 trial of C-1101 and develop scientific foundation and intellectual property portfolio.
- Total raised
- $45M to date
- Checked
- Announced by the company